Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVAC-2 in healthy adults
NCT04702178Phase 1Completed
- Sponsor
- University of Saskatchewan
- Start
- Feb 2021
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of COVAC-2 in coronavirus disease 2019 (COVID-19) (10 arms), sponsored by University of Saskatchewan. Primary endpoint: Adverse Events. Started Feb 2021; status: completed.
02
Drugs
COVAC-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04702178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702178.